EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prevalence of major INSTI and HIV-1 drug resistance mutations in pre- and antiretroviral-treated patients in Indonesia

Fauzia A Djojosugito, Arfianti Arfianti, Rudi Wisaksana, Fajri M Siregar, Nasronudin Nasronudin, Brian E Rachman, Siti Q Khairunisa, Agnes R Indrati

Narra J · 2024

DOI: 10.52225/narra.v4i3.1022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Narra J, 2024. Verfasst von Fauzia A Djojosugito und 7 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral Program in Medical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia. Hauptthemen laut MEDLINE: HIV Infections, Drug Resistance, Viral, HIV-1, HIV Integrase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Indonesia has one of the highest HIV infection rates in Southeast Asia. The use of dolutegravir, an integrase strand transfer inhibitor (INSTI), as a first-line treatment underscores the need for detailed data on INSTI drug resistance mutations (DRMs). Currently, there is a lack of comprehensive data on DRMs INSTI and other HIV drug resistance in Indonesian patients, both pre- and post-treatment. The aim of this study was to identify the subtypes and drug resistance mutations of the protease, reverse transcriptase, and integrase genes in both treatment-naive and ARV-treated patients in Bandung, West Java, Indonesia. A cross-sectional study was conducted involving HIV-positive patients at Hasan Sadikin Hospital, Bandung, Indonesia, from September 2022 to January 2023. The patients were categorized into two groups: ARV-treated and pre-treatment patients. Peripheral blood mononuclear cells (PBMCs) were processed for DNA extraction, followed by amplification and sequencing of the pol gene to detect mutations and subtypes. The study found that the predominant subtype was CRF01_AE, accounting for 85.4% and 69% of pre-treatment and treated patients, respectively, followed by recombinant forms such as A1/CRF01_AE, CRF01_AE/CRF02_AG, subtype B, and other subtypes. Among ARV-treated/INSTI-naive patients, major INSTI DRMs R263K and Y143H were identified, while pre-treatment patients exhibited accessory integrase DRMs. The most common DRMs detected were non-nucleoside reverse transcriptase inhibitor (NNRTI) DRMs, with prevalences of 14.6% and 7% in pre-treatment and ARV-treated patients, respectively. In conclusion, CRF01_AE emerged as the predominant subtype in both pre-treatment and ARV-treated patients in Bandung, underscoring the necessity for ongoing surveillance of integrase DRMs, particularly given the presence of major INSTI DRMs in patients undergoing INSTI treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsDrug Resistance, ViralHIV-1HIV Integrase InhibitorsHumansIndonesiaMaleCross-Sectional StudiesFemaleAdultMutationPrevalenceMiddle AgedPyridonesPiperazinesOxazinesPyridazinesHeterocyclic Compounds, 3-RingHIV IntegraseDolutegravir

Stichwörter der Autor:innen

HIV-1INSTIdrug resistancemutationsubtype

Substanzen

HIV Integrase InhibitorsPyridonesPiperazinesOxazinesPyridazinesHeterocyclic Compounds, 3-RingHIV IntegraseDolutegravir

Autor:innen und Institutionen

  • Doctoral Program in Medical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
  • Department of Microbiology, Faculty of Medicine, Universitas Riau, Pekanbaru, Indonesia.
  • Department of Medical Biology, Faculty of Medicine, Universitas Riau, Pekanbaru, Indonesia.
  • Research Centre for Care and Control of Infectious Disease, Universitas Padjadjaran, Bandung, Indonesia.
  • Department of Internal Medicine, Hasan Sadikin Hospital, Bandung, Indonesia.
  • Department of Biochemistry, Faculty of Medicine, Universitas Riau, Pekanbaru, Indonesia.

Zitieren

APA

Djojosugito, F. A., Arfianti, A., Wisaksana, R., Siregar, F. M., Nasronudin, N., Rachman, B. E., Khairunisa, S. Q., & Indrati, A. R. (2024). Prevalence of major INSTI and HIV-1 drug resistance mutations in pre- and antiretroviral-treated patients in Indonesia. Narra J. https://doi.org/10.52225/narra.v4i3.1022

Vancouver

Djojosugito FA, Arfianti A, Wisaksana R, Siregar FM, Nasronudin N, Rachman BE, et al. Prevalence of major INSTI and HIV-1 drug resistance mutations in pre- and antiretroviral-treated patients in Indonesia. Narra J. 2024. doi:10.52225/narra.v4i3.1022

BibTeX
@article{Djojosugito2024,
  author = {Djojosugito, Fauzia A and Arfianti, Arfianti and Wisaksana, Rudi and Siregar, Fajri M and Nasronudin, Nasronudin and Rachman, Brian E and Khairunisa, Siti Q and Indrati, Agnes R},
  title = {Prevalence of major INSTI and HIV-1 drug resistance mutations in pre- and antiretroviral-treated patients in Indonesia},
  journal = {Narra J},
  year = {2024},
  doi = {10.52225/narra.v4i3.1022}
}
Kostenlos starten →